| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Ingenol-5,20-acetonide-3-O-angelate does not have a direct biological target itself, as it is a synthetic intermediate. Its primary utility is as a precursor for Ingenol Mebutate, which targets the protein kinase C (PKC) family. However, the compound itself may share some structural and biological properties with other ingenol derivatives.
|
|---|---|
| ln Vitro |
In vitro, the compound's activity is not directly studied, as it is not a final drug. Its role is in the chemical synthesis process. However, as a diterpenoid, related compounds show potent bioactivity, and the intermediate may be used in assays to confirm its identity and purity. Its physicochemical properties, such as its molecular weight and structure, are characterized using techniques like HPLC and NMR.
|
| ln Vivo |
In vivo, Ingenol-5,20-acetonide-3-O-angelate is not used therapeutically. Its significance is that it is a key intermediate in the manufacture of Ingenol Mebutate, an approved drug. Therefore, its in vivo relevance is tied to the safety and efficacy of the final drug product. Any in vivo activity would be attributed to the final drug after conversion.
|
| Enzyme Assay |
The in vitro assay for this compound is not a biological assay but an analytical one. High-performance liquid chromatography (HPLC) is used to assess the purity and identity of the intermediate during the synthesis process. Mass spectrometry (MS) and nuclear magnetic resonance (NMR) spectroscopy are used to confirm its chemical structure and molecular weight.
|
| Cell Assay |
In vitro cell culture studies are not applicable to this synthetic intermediate. It is not used as a treatment or a probe in cell-based experiments. Its application is limited to the chemical and pharmaceutical manufacturing process, where its stability and reactivity are characterized, rather than its biological activity in cells.
|
| Animal Protocol |
In vivo animal experiments are not conducted with this intermediate. Its role is purely in the synthetic pathway for the drug. Any animal studies would be performed with the final formulated drug product, Ingenol Mebutate, to assess its efficacy in treating actinic keratosis, for which it has been approved.
|
| ADME/Pharmacokinetics |
Ingenol-5,20-acetonide-3-O-angelate is a solid, white crystalline powder. It is soluble in methanol, ethanol, and DMSO. It has a molecular weight of 470.60 g/mol and is typically stored at -20°C or under refrigeration to maintain stability. As a synthetic intermediate, it is handled under controlled conditions to prevent degradation.
|
| Toxicity/Toxicokinetics |
Toxicological data for this intermediate are limited to its handling in a manufacturing environment. It is not a final therapeutic agent, so comprehensive toxicity studies are not typically performed. However, as a chemical reagent, standard safety precautions should be followed, including the use of personal protective equipment to avoid exposure.
|
| Additional Infomation |
Ingenol-5,20-acetonide-3-O-angelate is exclusively a pharmaceutical intermediate for the synthesis of Ingenol Mebutate (Picato®). It has no other clinical applications. Its importance lies in its role as a key starting material for the commercial production of a drug used to treat actinic keratosis, a precancerous skin condition.
|
| Molecular Formula |
C28H38O6
|
|---|---|
| Molecular Weight |
470.6
|
| Exact Mass |
470.266
|
| CAS # |
87980-68-5
|
| PubChem CID |
71482499
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
582.2±50.0 °C at 760 mmHg
|
| Flash Point |
187.4±23.6 °C
|
| Vapour Pressure |
0.0±3.7 mmHg at 25°C
|
| Index of Refraction |
1.573
|
| LogP |
6.35
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
34
|
| Complexity |
1050
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
C/C=C(/C)\C(=O)O[C@H]1C(=C[C@@]23[C@@]1([C@H]4C(=C[C@H](C2=O)[C@H]5[C@H](C5(C)C)C[C@H]3C)COC(O4)(C)C)O)C
|
| InChi Key |
STFFIQHUWFISBB-YCAZZORDSA-N
|
| InChi Code |
InChI=1S/C28H38O6/c1-9-14(2)24(30)33-22-15(3)12-27-16(4)10-19-20(25(19,5)6)18(21(27)29)11-17-13-32-26(7,8)34-23(17)28(22,27)31/h9,11-12,16,18-20,22-23,31H,10,13H2,1-8H3/b14-9-/t16-,18+,19-,20+,22+,23-,27+,28-/m1/s1
|
| Chemical Name |
[(1S,4S,5S,6R,13S,14R,16R,18R)-5-hydroxy-3,8,8,15,15,18-hexamethyl-19-oxo-7,9-dioxapentacyclo[11.5.1.01,5.06,11.014,16]nonadeca-2,11-dien-4-yl] (Z)-2-methylbut-2-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~106.25 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1249 mL | 10.6247 mL | 21.2495 mL | |
| 5 mM | 0.4250 mL | 2.1249 mL | 4.2499 mL | |
| 10 mM | 0.2125 mL | 1.0625 mL | 2.1249 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
